Circulating microRNAs as a Prognostic Tool to Determine Treatment Efficacy in Lung Cancer Patients Undergoing Pembrolizumab PD-1 Blockade Immunotherapy.

Cancers (Basel) · 2024 · PMC11674096 · PMID 39766101

Europe PMC DOI

hedged sentence

0.1380

closest p · 2.8× alpha

0.1380

boldest claim

The sentences

a nonsignificant trendp = 0.138not close (p > 0.1)

However, the expression level one of the measured miRNAs, miR378c, showed a nonsignificant trend toward upregulation in response to treatment ( p = 0.138) ( Figure 2 A).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.